AstraZeneca Pharma India Limited (ASTRAZEN) — Announcement | 25 August 2026

25 August 2026 · NSE Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Delhi High Court stays NPPA demand notice on Betaloc-50 pricing dispute

🔄 What Changed

Court stayed NPPA's demand notice operation pending February 10, 2027 hearing

🔮 What's Next

None

💡 Investor Takeaway

The court pause reduces immediate pricing risk but leaves potential recovery liability unresolved until 2027.

⚠️ Risks

None

AstraZeneca Pharma India Limited disclosed that the Delhi High Court stayed an NPPA demand notice alleging overcharging on Betaloc-50 until February 10, 2027, subject to depositing 15% of the disputed amount. The filing references SEBI Regulation 30 disclosures and attached annexures detailing the legal action and alleged violations under the Drugs Prices Control Order.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ASTRAZEN ✨ Ask AI About This

About AstraZeneca Pharma India Limited (ASTRAZEN)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹15,635.88 CrP/E: 92.2ROE: 19.4%ROCE: 26.8%Div Yield: 0.58%

View full ASTRAZEN stock details →

📡 Get AI alerts when ASTRAZEN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ASTRAZEN — Free

💡 Ask AI about this filing

"What is the exact disputed amount in the NPPA notice?""When will the 15% deposit be made and from which financial source?""How does this affect future drug pricing compliance timelines?"

Ask AI Free →

📊 More ASTRAZEN filings

🔴 Announcement — 18 September 2026AstraZeneca Pharma India disclosed a penalty of Rs.1.88 lakh imposed by the Registrar of Companies f...
Announcement — 15 September 2026AstraZeneca Pharma India Ltd announced that its trading window will close on September 16, 2026, to ...
🔴 Announcement — 15 September 2026AstraZeneca Pharma India announced the resignation of Dr. Sandeep Arora, Director of Medical Affairs...
🔴 Announcement — 2 September 2026AstraZeneca Pharma India disclosed its ESG rating of 64 from Crisil ESG Ratings, based on FY2026 pub...
Announcement — 24 August 2026AstraZeneca Pharma India Limited disclosed its ESG rating of 57 from Crisil ESG Ratings, based on pu...

See all ASTRAZEN filings →

🔥 Also filed on 25 August 2026

EPLEPL LimitedAnnual Report AMANTAAmanta Healthcare LimitedAnnual Report ZEELZee Entertainment Enterprises LimitedAnnual Report FINKURVEFinkurve Financial Services LimitedCorporate Action EPLEPL LimitedAnnual Report ARVINDArvind LimitedAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ASTRAZEN files new disclosures

Track ASTRAZEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.